## Index

Adorno, Theodor, 109, 311  
Agriculture, 10  
Ahrendt, Hannah, 200, 203, 214n5, 214n10, 214n13  
Alchemy, 129–130, 133–135, 156  
Allianz, 297  
Allison, Henry A., 224  
Ambrière, Madeleine, 140n11  
Amyris Biotechnologies (company), 3, 272  
Androids, 127  
Angell, Marcia, 234  
Animal husbandry, 25–26, 33, 158  
Animal rights, 138, 299  
Anthropology of the Contemporary Research Collaboratory (ARC), 267, 286, 288n8  
Antibiotics, 43–44, 195  
Anticipatory governance, 276  
Applegate, John S., 83n2  
Appleton, Josie, 118  
Aquinas, Thomas, 127, 139n1  
Arcuri, Alessandra, 91, 94  
Aristotle, 126–127, 129, 131, 154, 224, 253n1, 337, 338, 214n14  
Artificial cells. See Protocells  
Artificial life, 89, 136, 140n13, 150, 201, 223, 239–246, 247, 248, 249, 252, 323  
hard, 239–240  
soft, 136, 239–240, 242  
wet, 239–240, 242–244 (see also Protocells)  
Asilomar (1975 conference on recombinant DNA), 23, 42, 189, 192  
Automata, 128, 149–150, 153, 156–157, 159, 160, 161  
Bacon, Francis, 127, 155, 156  
Bacteria, 1, 3, 8, 26, 191, 192, 194, 283, 316. See also Escherichia coli  
comparison of protocells with, 49–50, 58, 64–65  
Badiou, Alain, 288n6  
Balzac, Honoré de, 134, 140n11  
Barnes, Barry, 330  
Barrett, Katherine, 70, 83n2, 83n6  
Barry, Andrew, 268  
Bartel, David P., 4  
Beauchamp, Tom, 257n12  
Beck, Ulrich, 109, 203, 214n12, 273  
Bedau, Mark, 12, 46, 65, 76, 79, 82, 102, 143, 199, 212, 213, 239–240, 241, 245, 248, 258n17, 330, 346  
Bender, Wolfgang, 310, 317  
Benkler, Yochai, 168, 171, 172, 178  
Bennett, Charles H., 241  
Bennett, Gaymon, 11  
Bensaude-Vincent, Bernadette, 134  
Bentham, Jeremy, 138  
Berg, Paul, 23, 42, 189  
Bergler, R., 292  
Berkeley (university), 264, 265, 267, 283  
Berube, David M., 296  
Best, Robert, 315
Better Regulation Commission, 110
Bewers, J. M., 74
Biagioli, Mario, 168
Bible, 126, 148, 346–347n1
BioBricks, 151, 156, 159, 169, 171–172, 177, 179, 186–187, 194, 264
Bioethics and bioethicists, 161, 200, 268–269, 279–280, 281, 298, 329
Biofuels, 173, 264, 283
Biological weapons, 183, 189–190, 208, 309, 317–318
Biological and Toxic Weapons Convention (1982), 189
synthetic biology applications to, 190
Biomedical science, 10, 12, 168, 206
Biosecurity, 158, 184, 208, 267, 286
Biosensors, 7, 50, 186, 194. See also Protocells, products
Biotechnology
industry, 183, 187, 192
patents (see Patents, biotechnology)
Bioterrorism, 8, 13, 160, 167, 172, 264, 334–335
Biological weapons, 183, 189–190, 208, 309, 317–318. See also Dual use
Boas, Marie, 107
Bocci, Velio, 43
Bodansky, Daniel, 78
Böhme, Gernot, 200, 205, 207
Boltanski, Luc, 273, 282
Boniono, Giovanni, 10, 335
Böschen, Stefan, 211
Bostanci, Adam, 319
Bovine growth hormone, 72
Boyle, Robert, 131, 137
Brannigan, Michael C., 31
Breyman, Steve, 98
Brody, Baruch, 231, 234
Brooks, Rodney, 7, 239
Brothaerts, Wim, 196
BSE (bovine spongiform encephalopathy), 112–114
Burden of proof, 40–41, 61–62, 77–78, 343. See also Decision theory, burden of proof in
Burgess, Adam, 114, 118
Buss, Klaus-Peter, 205
Callahan, Daniel, 153–154
Camazine, Scott, 241
CAMBIA-BIOS Project, 166, 168
Canguilhem, Georges, 229, 234, 255n3
Carr, Edward H., 108
Carson, Rachel, 23
Cartagena Protocol on Biosafety, 72, 90
Castells, Manuel, 208, 216n29, 216n30
Caution, 44–45, 95–102, 212
thick descriptive content of, 97–98
Cell-free extract, 4, 6
Cello, Jeronimo, 137, 190
Cell phones, 20, 40, 42, 102, 105, 112, 114, 293
risks of (see Risk of cell phones)
Cellular automata (CA), 240
Center for Nanotechnology in Society at Arizona State University (CNS-ASU), 275–276
Chabon, Michael, 148
Chaitin, Gregory, 241
Chan, Leon Y., 171
Chapman, Graham, 20
Chemicals
ethical objection to basic research, 134–136, 139
industry, 10, 12
regulation of (see Regulation of chemicals)
risks of (see Risk of chemicals)
toxicity of (see Toxicity of chemicals)
Cho, Mildred, 8
Christianity, 131, 133, 137, 139
Chyba, Christopher F., 190
Clark, Julie, 190
Cloning, 10, 27, 31, 32, 33, 148, 199, 200, 296, 299, 313
Cobb, Michael D., 301
Codon Devices (company), 3, 13n1, 272
Cohlan, Andy, 23
Coglianese, Cary, 106
Commons Science and Technology Committee (UK), 106
Comstock, Gary L., 32, 46n1, 46n3, 76
Conference of the Parties to the Convention on Biological Diversity, 82n1
Consequentialism. See Ethics, consequentialist
Cost-benefit analysis, 81, 82, 233. See also 
Decision theory; Risk, analysis of 
Courage, 32, 44–45, 97, 99, 212
Cousin, Jennifer, 319
Cox, Jonathan P. L., 185
Cranor, Carl, 12, 51, 52, 61
Crashtest.com, 24
Creationism, 127, 131–133, 322, 324, 326, 327
Crichton, Michael, 13n2, 31, 199, 200. See also Prey
Cross, Frank B., 83n7, 83n9
Curtis, George T., 170

Dabrock, Peter, 204, 205, 206
D’Alembert, 128, 139n2
Danish Board on Technology, 301
DARPA (Defense Advanced Research Project Agency), 193
Darwall, Stephen, 253n1
Darwin, Charles, 108, 132–133, 140n10, 144
DBCP (pesticide), 42
DDT (pesticide), 23
Deamer, David, 4, 7, 49, 89, 151, 242, 295, 308
Decision making about protocells (see Protocells, decision making about)
public participation in, 11, 105, 115–119, 284, 297, 300–302
scientific authority in, 105–119
stakeholders in, 118
standards of conduct in, 37
transparency of, 117
values in, 75–76, 79, 82, 116–119
Decision theory, 12, 37–38, 39–45. See also 
Precautionary principle; Risk
burden of proof in, 40–41
decision trees and, 37–38
decisions in the dark, 38, 39–45
decisions under risk, 37
decisions under uncertainty, 38
distributive justice and, 36
expected value in, 37
freedom of inquiry and, 36
good judgment and, 38, 45
harms of inaction, 42–43, 45
innocence until proven guilty, 40
minimax, 38
utilitarianism and (see Ethics, utilitarian)
utility in, 36, 38
vagueness in, 40
Deleuze, Gilles, 274
Demos (UK think tank), 28
Dennett, Daniel, 224
Department of Agriculture (DOA), 188
Department of Health and Human Services (DHHS), 61
Descartes, Rene, 128, 139n2
Devill, Adrian, 343
Dewannieux, Marie, 190
Dewey, John, 287
Diderot, Denis, 159
DNA, 185
recombinant, 23, 42, 136, 160, 168–169, 183, 189 (see also Genetic engineering; Moratorium letter)
synthesis, 3, 165, 169, 172, 176, 179, 183, 186, 190, 264
use in bottom-up protocell construction, 4
Dobson, Andrew, 46n2
Doll, Richard, 113
Dolly (cloned sheep), 31
Doomsday scenarios, 32, 39–40, 92
Dorff, Elliot, 148
Dorrell, Stephen, 113
Drexler, Eric, 8, 300, 303n6
Drug Enforcement Agency (DEA), 188–189
Dual use, 201, 210, 214n6, 317, 318
Dufresne, Guillaume, 174
Dupré, John, 325, 330
Durodić, Bill, 11, 12, 71, 73, 75, 76, 111, 115, 116, 119
Dworkin, Ronald, 94
Eco, Umberto, 157
Eisenberg, Rebecca S., 166
Index

Eisenstein, Elizabeth, 228
Ekland, Eric H., 5
Ellul, Jacques, 228, 234, 256–257n10
Emergence, 170, 176–179, 241–242, 248, 252, 280–282, 284, 286
strong, 241, 252
Emmeche, Claus, 140n13, 240, 241, 242
Endy, Drew, 168, 169, 171, 185
Engelhardt, H., 299
Enright, Mark C., 43
Environmental Defense Fund (EDF), 59
Environmental Protection Agency (EPA), 59, 188
Equipment (anthropological concept), 267, 268, 279, 281
Erbschloe, Michael, 191
Erickson, Kent L., 43
Escherichia coli, 160, 186
ETC Group (Action Group on Erosion, Technology and Concentration), 46n7, 172, 175, 176, 297
Ethical concerns about protocells, 8, 296. See also Synthetic biology, ethical issues particular to
commodification of life, 32, 33–34, 45, 159, 162n3, 318
hubris and hype, 321
playing God (see Playing God) reductionism, 32, 34, 45, 162n3
religious doctrine and, 35
slippery slope argument and, 342–343
unnaturalness, 12, 33, 45, 159, 162n3
violating the sanctity of nature, 32, 153
Ethical, Legal, and Social Issues (ELSI), 11, 211, 266, 267, 298
Ethicists, 11, 117
Ethics
consequentialist, 92, 138, 253n1
different ways of understanding, 298–299
downstream, 223, 233, 235–236, 247
environmental, 298
ethical codes, 27
ethical norms, 1, 224–230, 234, 235–236, 247–248, 254–255n2, 255n3, 258n20
ethical theory, 253, 254n1
flourishing and, 224–225, 226, 229–230, 280
free agency and, 224–225, 237–238
Kantian, 52, 204, 224, 225, 228, 256n7
post hoc (see Ethics, downstream)
precautionary, 236
public dialogue and, 296–298, 300–302
radical ethical crises, 228–230
science and, 230–235, 247–250, 309
responsibility and, 225–226, 344–346
upstream, 12, 28, 224, 236–238, 246, 252–253, 255n2, 257n15
utilitarian, 32, 35–36, 45, 224–225, 299
Eurochem, 102
European Center for Living Technology (ECLT), 213, 295
European Commission, 27, 72, 78, 81, 83n2, 114, 115, 169, 275, 297
European Environment Agency, 112
European Union, 27, 41, 82, 169, 216n28, 243, 278n3
European Union Joint Research Centre, 20, 22
Evolution, volitional, 237–238
Farley, John, 126, 133, 140n8
Feenberg, Andrew, 201
Ferber, Dan, 189
Fisher, Elizabeth, 91, 94
Fisher, Erik, 276
Fitzpatrick, Michael, 112, 115, 116
Fleck, Ludwik, 326–327
Fletcher, Joseph, 154
Food and Drug Administration (FDA), 62, 71, 73, 81, 188–189, 195, 228, 231
Foot, Philippa, 96, 97, 224
Foster, Kenneth, 78, 83n2
Foucault, Michel, 281
Fox-Keller, Evelyn, 206, 263, 312, 329
“Frankencells” (tag word attached to protocell research), 8, 33, 200
Frankenstein (myth/novel), 148, 150, 200, 214n4, 293
Frankfurt, Harry, 256n7
Fraser, Claire M., 2
French, Peter A., 96
Freud, Sigmund, 150, 153
Fukuyama, Francis, 236
Furedi, Frank, 105, 117

Geiser, Ken, 41
Geison, Gerald L., 132, 133
Genetic algorithms (GAs), 244–245, 252
Genetic engineering, 3, 8, 10, 38, 42, 43, 45, 136, 158–159, 160 183, 189.
See also DNA, recombinant
Gibbons, Michael, 254n1, 275
Gibson, Daniel G., 3
Giddens, Anthony, 200, 204, 214n12
Gilland, Tony, 83n3, 115
Gillette, Clayton P., 60
Gillis, Justin, 2, 3, 8
Gillott, John, 106
Gjerris, Mickey, 11, 299
Godin, Benoit, 234
Goethe, Johann W. von, 139n4
Goklany, Indur M., 79, 83n7, 84n9, 343
Goldberg, Susanne M., 192
Golem (animated being from Jewish folklore), 127–129, 148, 313
Goodwin, William, 150
Gottlieb, Scott, 188
Gould, Stephen J., 238, 241, 242
Graham, John D., 89
Gray, John S., 74, 75
Gray, Michael W., 26
Green fluorescent protein (GFP), 6, 157, 186
Grinbaum, Alexei, 296
Guan, Y., 190

Habermas, Jurgen, 313
Hacein Bey-Abina, Salima, 322
Haker, Hille, 207
Hammit, James K., 79
Hampson, Norman, 107
Hanczyc, Martin M., 5, 145
Hansen, Janus, 293
Hansson, Sven O., 102
Hantsche, Brigitte, 11
Haraway, Donna, 209
Hargreaves, Ian, 105
Harms, William, 238, 254n1, 255n3
Harremoës, Poul, 101, 343
Harris, John, 93
Hauchler, Ingomar, 208
Hauser, Marc D., 253n1
Hauskeller, Christine, 12, 313
Havelock, Eric, 228
Hede, Karyn, 189
Hegel, Georg W. F., 239
Heidegger, Martin, 26, 155, 156
Heller, Arno, 204
Heller, Michael A., 166, 167, 168, 187
Henkel, Joachim, 171, 176
Hero of Alexandria, 128
Hessel, Andrew, 10, 188
Hill, Austin B., 113
Hill, Donald, 128
HIV, 43, 188
HM Government, UK, 297
Hoban, Thomas, 20
Hobbes, 128, 139n2
Hobsbawm, Eric, 108
Holland, John H., 244
Holm, Søren, 83n8, 93
Homunculi, 127, 129–130, 139n4, 156, 313
Honnefelder, Ludger, 200, 207, 208, 215n25
Hood, Christopher, 118
Horkheimer, Max, 311
House, Lisa, 20
House of Commons (UK), 113
House of Lords (UK), 105
Howard Hughes Medical Institute (HHMI), 144, 145, 146, 162n1
Huff, James, 59
Human Fertilisation and Embryonology Authority (HFEA), 309
Human Genome Project, 11, 194, 267, 279, 313, 329
Humanoids, 127–130
Hume, Mick, 110
Hursthouse, Rosalind, 99
Hutchison, Clyde A., 2
Huxley, Aldous, 135
Huxley, Thomas H., 214n1
Idel, Moshe, 128, 129
Independent Expert Group on Mobile Phones (IEGMP), 112, 114
InnoCentive (company), 193
Institute for Biological Energy Alternatives (IBEA), 173
Intellectual property. See Patents
Ishikawa, Keitaro, 6
Islam, 131, 148
Jackson, Ronald J., 190
James, Simon P., 26
Jan, Tracy, 194
Jaquet-Droz, 149–150
Jasanoff, Sheila, 278
Jefferson, Richard, 166
Jensen, Ole, 302n1
Joerges, Bernward, 201
Johnson, Brian, 11
Jonas, Hans, 199, 201, 203, 204, 209, 210, 225, 228, 236
Jones, Phillip B. C., 72, 78, 83n2
Jonsen, Albert, 227, 269
Jowell, Tessa, 114
Joy, Bill, 8, 38, 211
Judaism, 128, 148
Kabbalah (Jewish), 128
Kaiser, Jocelyn, 173, 175
Kant, Immanuel, 52, 128, 139n2, 204, 224–225, 228, 256n7. See also Ethics, Kantian
Kaplinsky, Joe, 114
Karpenko, Vladimir, 130
Kass, Leon R., 46n1, 46n2
Kastner, Justin, 72
Kennedy, Ian, 117
Kevles, Daniel, 263
Khushf, George, 11, 234, 256n16
Kitcher, Philip, 255n3
Kline, Morris, 106
Knorr-Cetina, Karin, 169
Koestler, Arthur, 257n13
Koselleck, Reinhardt, 274
Krebs, John R., 23
Kuhn, Thomas, 157n11
Kumar, Sapna, 169, 176
Lakhani, Karim, 193
Lamarck, Jean-Baptiste, 132, 140n8, 140n9
Lander, Eric S., 194
Langlois, Richard N., 170
Lartigue, Carole, 3, 264
Lassen, Jesper, 296
Latour, Bruno, 157n14, 202, 230
Laughlin, Robert B., 242
Law patent, 165, 169–170, 179 (see also Patents)
premarket and postmarket, 60–63
science and, 64
tort, 71
Lawrence, Stephen, 117
Lee, T. R., 292
Legname, Giuseppe, 190
Leibniz, Gottfried, 131
Levinas, Emmanuel, 155
Levskaya, Anselm, 186
Lewis, C. S., 153
Lieverman, Adam, 70, 73
Life commodification of (see Ethical concerns about protocells, commodification of life)
definition of, 137, 307, 310–311, 313, 325–328, 329
intrinsic value of, 32–35
origin of, 136, 143, 144–145, 161, 242–243, 246, 322, 324–327
patenting of (see Patents of life forms)
reverence for, 34
sanctity of, 12
spontaneous generation of, 126–127, 131–133
synthesis of (see Synthesis of life)
Lindemann, Gesa, 312, 324, 330
Linneus, 131
Linux (operating system). See Open source,
 Linux operating system as an example of
Lippmann, Edmund O. v., 126, 131, 132, 140n8
Living technology, 7–8
Longino, Helen, 201, 214n8
Los Alamos National Laboratories (LANL), 243, 258n17
protocell (see Protocell, Los Alamos)
LS9, Inc., 3
Lucentini, Jack, 152
Luhmann, Niklas, 271–272
Luigi, Pier, 4, 242
Macintyre, Alasdair, 100, 268
McKibbin, Bill, 236
McNeill, William H., 113
Magnus, Albertus, 127
Mai, Volker, 43
Malaria, 264
Manchester, William, 106
Manson, Neil A., 92
Marguet, Philippe, 169
Margulies, Anne H., 194
Marx, Karl, 109
Maskus, Jerome H., 180n3
Massachusetts Institute of Technology (MIT), 172, 186, 194, 264, 265, 283.
 See also BioBricks; Registry of Standard Biological Parts
Maurer, Stephen M., 160, 192
Meek, James, 106
Mele, Alfred, 224
Merchant, Carolyn, 312
Merges, Robert, 177
Merkle, Ralph, 8, 9, 39
Metabolomics, 236
Meyer, Gitte, 295
Michaels, David, 64
Mieth, Dietmar, 23
Milgram, Elijah, 228
Miller, Harold, 73, 79, 83n8
Miller, Henry L., 89
Miller, Karl E., 43
Miller, Stanley L., 140n14
Ministry of Agriculture Fisheries and Food (MAFF), 113
Ministry of the Environment, 82n1
Mirowski, Phillip, 168
Mobile phones. See Cell phones
Modularity (concept), 168–172, 179, 234
Monnard, Pierre-Alain, 4
Mooney, Chris, 8, 200
Moratorium letter (on recombinant DNA, 1974), 42, 189
Morris, Julian, 46, 71, 72, 77, 78, 112, 343
Moss, Lenny, 324, 329
Municipal Code Corporation, 82n1
Murray, Fiona, 168
Mycoplasma genitalium, 2–3, 173, 174, 242
Myhr, Anne I., 89
Nagel, Thomas, 300
Nanotechnology, biotechnology, information technology and cognitive science (NBIC) convergence, 236
NASA (National Aeronautics and Space Administration), 162n2
National Academy of Sciences of the USA, 42
National Commission for the Protection of Human Subjects, 234, 257n12, 269
National Research Council (NRC), 59, 60, 61, 63, 64, 192
National Science Foundation (NSF), 267
Newman, William R., 128, 130, 139n3, 140n5
Newton, Isaac, 131
Nielsen, Annika P., 300
Nielsen, Peter, 5
Nilsson Jacobi, Martin, 311
Nixdorff, Kathryn, 317
Nongovernmental organizations (NGOs), 20, 21, 23, 111
Noireaux, Vincent, 6, 152, 242, 308, 314, 315
Norton, Bryan G., 247
Nowotny, Helga, 199, 200, 203, 205, 207, 274–275
Nussbaum, Martha, 224

Oberholzer, Thomas, 4
Obrist, Barbara, 130
Office of Technology Assessment (OTA) of the US Congress, 59
O’Malley, Maureen, 174
O’Neill, Brendan, 113
O’Neill, Onora, 294, 295
Ong, Walter, 228
Open source, 10, 166, 168, 172, 175–176, 179, 184–196
Linux operating system as an example of, 10, 192–193
O’Riordan, Timothy, 111, 343
OSPAR Commission, 82n1
Ovid, 127
Oyama, Susan, 238, 254n1, 324
Ozick, Cynthia, 148

PACE (Programmable Artificial Cell Evolution) project, 19, 27, 28, 243, 245, 247, 258n17, 296, 303n2
Paracelsus, 129, 139n4, 156
Parliamentary Office for Science and Technology (POST), 105
Parke, Emily, 12, 41, 46n4, 70, 83n2, 103, 213, 330, 346
Pascal’s Wager, 92–93
Pasteur, Louis, 132, 133
Patents, 10, 187–188, 196, 272, 320
biotechnology, 187–188
in biomedicine, 167
law and, 165
(see also Patents, Mycoplasma laboratorium)

Mycoplasma laboratorium, 3, 172–175, 177
public transparency and, 166
software, 188
Patterson, George, 302
Paul, Ellen F., 224
Pauly, Philip, 263
Pedagogy, 279
Pejčic, Bobby, 191
Pence, Gregory, 274
Peng, Zhaohui, 191
Peterson, Eugene, 347n1
Peterson, Martin, 91, 99
Pharmaceutical industry, research, testing and regulation process, 231–233, 234
Philo of Byzantium, 128
Philosophy of science, 230, 329
Pick, Daniel, 108
Pindar, 128
Playing God (criticism of protocell research), 12, 32, 34–35, 45, 89, 126, 130, 133, 137 138–139, 154, 202, 313, 340–342, 345
Plesnner, Helmut, 312, 324
Pliny, 127
PNA (peptide nucleic acid), 5, 152, 243, 249–250, 258n18
Pohorille, Andrew, 4, 7, 49, 242, 295, 308
Poliovirus, 137, 190
Pomer, Philip, 256n6
Porritt, Jonathon, 111
Postman, Neil, 228
Potting, Alain, 10, 175
Pouchet, Felix, 132
Precaution, 114, 109, 114, 138, 160
Precautionary principle, the, 12, 27, 32, 41–44, 45–46, 69–82, 89–102, 112, 117, 343–344. See also Decision theory; Risk
argument against protocells from, 343–344, 345
criticism of, 41–44, 71–81
definition of, 41, 111
different interpretations of, 90–95
Index

directive for action in, 70, 76, 77, 79, 80, 82
emotions and, 75–76, 81
as an epistemic rule, 91, 93–94, 98–99, 101
forgone benefits and, 79–80, 82, 83n7
harms of inaction and (see Precautionary principle, the, opportunity costs of)
incoherence of (see Precautionary principle, the, self-contradiction of)
misapplication of, 72, 111
mistaken priorities and, 80, 82
operationality of, 78
opportunity costs of, 109
paralysis and (see Precautionary principle, the, self-contradiction of)
as procedure, 91, 94–95, 98–99, 101
regulation and, 72–73, 81
relevance to protocell research, 69, 82, 101–102, 247
as a rule of choice, 91–93, 98–99, 101
scope of, 70, 74, 76, 77, 80
self-contradiction of, 40, 76–77, 78, 82, 92, 99, 111
severity of, 70, 74, 76, 77, 79, 80, 82, 83n8
specificity of, 70
stifling innovations and, 79–80, 82, 83n8
strength of, 70
superfluousness of, 71–72, 81
trade protectionism and, 72, 81, 96
triggering factor of, 70, 76, 77, 80, 82
uncertainty and, 70
unknowability and, 77–78, 82
unsound science and, 74, 82, 83n5, 83n6, 112
vagueness of, 70–71, 78–79, 81, 82, 90
variability of, 70–71, 78–79
virtue approach to, 90, 95–102
worst-case scenarios and, 73, 112
*Prey* (Michael Crichton novel), 13n2, 31, 199
Price, Charles C., 135–136, 137
Probiotics, 43–44
Prometheus, 150
Proteomics, 236
See also Synthetic biology
bottom-up approach, 3–6, 137, 176, 177, 239, 243–244, 245–246, 251, 252, 264, 307, 314, 318, 322, 333, 341
by-analogy debate strategy applied to, 335–336, 345
creating vs. using, 334–335
decision making about, 39–45
containment of, 9–10
dual-use applications of (see Dual use)
ethical guidelines for, 161
ethical objections to (see Ethical concerns about protocells)
health and environmental consequences of, 319
language and self-representation issues with, 321
Los Alamos, 5–6, 52, 152, 243
medical applications of, 316
ontological debate strategy applied to, 336–339, 345
origin of life, relevance to (see Life, origin of)
patenting (see Patenting of life forms)
products, 1, 7–8, 49–50, 58, 63, 64, 173, 264, 283, 307, 314–315, 316–320, 334, 314–321
regulation of (see Regulation of protocells)
risk of (see Risk of protocells)
top-down approach, 2–3, 6, 137, 177, 239, 242, 251, 252, 264, 307, 314, 318, 322, 333
type-token debate strategy applied to, 339–340, 345
uncertain consequences of, 160–161
ProtoLife Srl, 13n1
Public Library of Science, 194
Purdy, Laura M., 312
Putnam, Robert D., 110
PVC (polyvinyl chloride), 73
Pygmalion, 128
Quijano, Romy F., 83n5
Rabinow, Paul, 11, 234, 254n2, 268
Raffensperger, Carolyn, 46n7, 83n2, 91
Rai, Arti, 168, 176, 188
Rasmussen, Steen, 2, 4, 5–6, 13n3, 50, 89, 137, 243, 248, 249, 264, 307, 310, 314
Raymond, Eric S., 193
Real-time technology assessment (RTTA), 276
Red blood cells, artificial, 1, 7
Redon, Richard, 192
Registry of Standard Biological Parts, 172, 176, 186, 194. See also BioBricks; Massachusetts Institute of Technology
Rehmann-Sutter, Cristoph, 324
Reiss, Michael S., 32, 46n3
Ribozymes, 5, 144
Rio Declaration, 72, 90, 91, 94
Robert, Jason S., 257n13, 258n19
Robinson, William C., 180n1
Roco, Mihail C., 296, 300, 303n7
Ropeik, David, 40, 42
Royal Commission on Environmental Pollution (RCEP), 105
Royal Society, 110, 112, 115, 257n15, 297, 301
Rubin, Charles T., 73
Russell, Colin A., 134
Sainsbury, D., 117
Saks, Michael J., 60
Index

Salek, Sam, 234
Sandin, Per, 12, 76, 83n2, 83n3, 90, 91, 93, 94, 95, 96
Sandler, Ronald, 297
Santillo, David, 78
SARS virus, 190
Satanism, 130
Saunders, Peter, 70
Scanlon, Thomas, 52
Schoeman, Ferdinand, 225
Scholem, Gershom, 128
Schon, Donald A., 225, 230
Schroedinger, Erwin, 147
Schudt, Karl, 96
Schummer, Joachim, 130, 132, 134, 135, 140n6
Schweitzer, Albert, 138
Science and technology
ethics and (see Ethics, science and)
problem-oriented assessment of, 309–310
public perception of, 8, 11, 13, 19–27, 167, 201, 211, 292–295, 311–313, 330
(see also Risk, perception of)
skepticism about, 295, 300–301
social progress and, 106–109, 110
values and, 109
Science studies, 230
Scientific American (magazine), 167
Scottish Council on Human Bioethics, 309
Self-assembly, 3, 238, 241, 242, 243–244, 245, 249–250, 252, 311, 324, 337
bottom-up, 241, 251, 252, 258n19
coupling with evolution, 244, 245
Selin, Cynthia, 303n5
Sen, Amartya, 225
Shapin, Steven, 268
Shelly, Mary, 125, 150
Sheridan, Barrett, 173
Sherwin, Susan, 312
Shreeve, James, 173, 175
Silver, Lee M., 31
Singer, Maxine, 189
Slovic, Paul, 50–51, 55–56, 57
SmallTimes, 292
Smith, Hamilton, 2–3, 8
Smith, John, 140n12

Soul, 130, 133, 138
Stanford Encyclopedia of Philosophy, 155
Stather, Marilyn, 277
Stem cells, 10, 19, 23, 27, 49, 69, 70, 308, 309, 313, 315, 316, 318, 320, 329
Stephens, Trent D., 41
Steward, Sir William, 114
Stewart, C. Neal, 20
Stich, Stephen, 37, 46n5, 92
Stikeman, Alexandra, 9
Stone, Marcia, 168
Sunstein, Cass R., 91, 92, 94, 99
Sustainability, 26
Synthesis of life
abhorrence of, 125, 137–139
causal determination and, 131
ethical assessment of, 125–130, 136
evolution and, 132–133
experimentation and, 131–132
hubris objection, 130, 134, 137 (see also Ethical concerns about protocells, hubris and hype)
motivation for, 136–139
playing God objection (see Playing God)
scientific fascination with, 125, 137–139
uncertain consequences of, 138
application to biological weapons
(see Biological weapons, synthetic biology applications to)
application to creation of designer pathogens, 190–191
bottom-up vs. top-down, 151, 177
(see also Protocells, bottom-up; Protocells, top-down)
ethical issues particular to, 160–161, 167
(see also Ethical concerns about protocells)
patenting (see Patenting of life forms; Venter, J. Craig, Mycoplasma laboratorium patent)
Synthetic Biology Engineering Research Center, the, (SYNBERC), 265–287
devices, 265
chassis, 265
Human Practices, 265, 280, 283–287
Mode One, 270–274, 275, 282, 283–284, 287
Mode Two, 274–278, 282, 284–285, 287
Mode Three, 278–282, 285–287
parts, 265
Synthetic Genomics, Inc., 3, 13n1
Szostak, Jack, 4, 5, 144–147, 149, 150, 151, 153, 155, 157, 161, 161n1, 242
Talmud, 126,
Tauber, Alfred I., 256n8
Taylor, Charles, 225
Tertullian, 140n6
Thalidomine, 23, 41
Theis, Morgan, 244–245, 247, 248, 251, 258n19
Thompson, Larry, 319
Thoreau, Henry David, 294
Tickner, Joel, 75, 83n5
Tomlinson, Sir Bernard, 113
Toulmin, Stephen, 298
Toxicity, 59, 73
of chemicals, 59
of cosmetics, 59
health hazard assessment, 59
of pesticides, 59, 60
of pharmaceuticals, 59, 60
Transcendence argument. See Playing God
Transgenetic. See Genetic modification
Trewavas, Anthony J., 23
Triant, Mark, 12
Tumpey, Terrence M., 190
Turnbull, H. W., 106

Umar, M., 148
Ungar, Sheldon, 110
United Nations, 41, 79, 82n1
United States Department of Energy, 2
Urea, 8
Urey, Harold C., 140n14
Utilitarianism. See Ethics, utilitarian
Variant Creutzfeldt-Jakob disease (vCJD), 113–114
Vaucanson, Jacques, 128
Venter Institute, the, 172, 174, 177
Venter, J. Craig, 2–3, 8, 33, 172–174, 175, 192, 209, 242, 325
global ocean sampling project, 175, 325
Mycoplasma laboratorium patent (see Patents, Mycoplasma laboratorium)
Venters, George A., 2001
Vesicles, 4, 6, 145–146
growth and division of, 5
Villarreal, Luis P., 26
Virgil, 127
Virtanen, 159
Viruses, 3, 9, 26, 149, 173, 190. See also Poliovirus
Vitalism, 134
Vogel, Gretchen, 320
Volokh, Eugene, 342

Waddington, Conrad T., 256n6
Walde, Peter, 4
Walden, Paul, 135
Walsh, John P., 168
Walton, Douglas, 342
Watson, James, 42, 43
Weber, Max, 270, 273, 278, 280
Weiss, Paul, 257n13
Wells, Herbert G., 125
Wheeler, Michael, 149
Wilsdon, James, 257n15
Wilson, Edward O., 236–238, 249
Wilson, James Q., 224
Wilson, Richard, 41
Wikipedia, 171, 194
Wiladavsky, Aaron, 73, 79, 83n8
Wilson, James M., 191
Wingspread Conference, 46, 91
Wittgenstein, Ludwig, 205, 208
Wolbring, Gregor, 150
Wolpe, Paul R., 148
Wolverhampton Electricity Supply, 20
Wood, Gaby, 150, 156, 157, 159
World Health Organization (WHO), 24, 43
World Trade Organization (WTO), 72
Wren, Jonathan D., 188
Wynne, Brian, 112, 118

X-Prize Foundation, the, 193

Yandle, Bruce, 72
Yesley, Michael, 211
Yomo, Tetsuya, 6

Zeitler, Uli, 299
Zimmer, Carl, 2
Zizek, Slavoj, 111
Zoloth, Laurie, 148